DDrare: Database of Drug Development for Rare Diseases

Searched query = "Myasthenia", "MG"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = 250 mg CK-2017357; 3,4-DAP; 3,4-Diaminopyridine; 3,4-diaminopyridine; 500 mg CK-2017357; ALXN1210; AMIFAMPRIDINA; AMIFAMPRIDINE; ARGX-113; ATG (rabbit); AZA; Abatacept; Abatacept Injection; Acetaminophen; Amifampridine; Amifampridine Phosphate; Anti-C5 antibody; Anti-Thymocyte Globulin; Azathioprine; B-peptide-CRM197 conjugate; BBR 2778; BELIMUMAB; BENLYSTA® (belimumab); BORTEZOMIB; Belimumab; Benlysta (belimumab); Bortezomib; CD19-directed humanised afucosylated monoclonal antibody; CELLCEPT; CFZ533; CV-MG01; Carmustine; CellCept; CellCept 500 mg; CellCept 500 mg film-coated tablets; CellCept 500 mg tablets; CellCept®500 mg tablets; Cellcept; Cellcept 500 mg tablets; Chloride; Cyclophosphamide; Cyclosporine; Cytarabine; DAP; DAS-001; DIFENIDRAMINA CLORIDRATO; Descartes-08; Difenidramina; Diphenhydramine; Diphenhydramine hydrochloride; ECULIZUMAB; EFALIZUMAB; EN101; EPHEDRINE HYDROCHLORIDE; Eculizumab; Efalizumab; Efedrina; Efgartigimod; Ephedrine; Etoposide; FIRDAPSE - 10 MG - COMPRESSE - USO ORALE - BLISTER(ALU/PVC/PVDC) 100 X 1 COMPRESSE; FIRDAPSE 10mg Tablets; Fc- and CDR-modified humanised monoclonal antibody against C5; Firdapse; G-CSF; GAMUNEX 10%; GB-0998 (Intravenous immunoglobulin); GSK1550188; Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF); HBM9161 Injection (340 mg); HBM9161 Injection (680mg and 340 mg); HIZENTRA ®; HUMAN NORMAL IMMUNOGLOBULIN (IV); Hematopoietic Stem Cell Transplantation; Hidrocloruro de efedrina; Human normal immunoglobulin; Human normal immunoglobulin G (IgG); IGIV-C; IMMUNOGLOBULIN G; INEBILIZUMAB; IVIG; IVIg; Immune Globulin (Human), 10% Caprylate/Chromatography Purified; Immune Globulin (Human), 10% Caprylate/Chromatography Purified (IGIV-C); Immune globulin; Inebilizumab; Influenza vaccine; Intravenous ImmuneGlobulin; Leflunomide; M281; M281 Injection; METILPREDNISOLONE; MONARSEN; MONITOR; MabThera; Mabthera; Magnesium; Magnesium sulfate; Melphalan; Mesna; Mestinon; Methotrexate; Methylprednisolone; Metilprdnisolone; Mutagrip; Mycophenolate; Mycophenolate Mofetil; Mycophenolate mofetil; Mycophenolate mofetil (CellCept); Mycophenolate mofetil [CellCept]; Mycophenolic acid; Other: Laboratory Biomarker Analysis; PARACETAMOLO; PIXANTRONE; PRIVIGEN; PYRIDOSTIGMINE; Paracetamolo; Phosphate; Pixantrone; Prednisolone; Prednisone; Prednisone - Azathioprine; Prednisone alone; Procedure: Autologous Hematopoietic Stem Cell Transplantation; Procedure: PLEX; Procedure: Peripheral Blood Stem Cell Transplantation; Procedure: Plasmapheresis; Procedure: Syngeneic Bone Marrow Transplantation; Procedure: thymectomy plus prednisone; Pyridostigmine; RC18 160mg; RC18 240 mg; RITUXIMAB; ROZANOLIXIZUMAB; RTX; RVT-1401; Rabbit; Raptiva; Raptiva 100 mg/ml powder and solvent for solution for injection; Ravulizumab; Rituximab; Rituximab (Rituxan); Rozanolixizumab; SALBUTAMOL SULFATE PH. EUR.; SOLIRIS; Salbutamol; Salbutamol 4Mg Tablet; Salbutamol WZF 4 mg; Sodium Chloride solution; Sodium chloride; Soliris; Subcutaneous immunoglobulins; Sulfate; Symptomatic Treatment, Steroids, Immunosuppressive Agents( azathioprine, tacrolimus, Mycophenolate Mofetil); Symptomatic Treatment, Steroids, Immunosuppressive Agents, Plasma Exchange(PE), Intravenous Immunoglobulin(IVIg); T-peptide-CRM197 conjugate; TAK-079; Tacrolimus; Tacrolimus capsule; Tetanus vaccin; Tofacitinib; Tofacitinib 5 MG; UCB7665; Ultomiris; Velcade; Velcade®; Zilucoplan; Zilucoplan (RA101495); [M281]; [NA]; [TAK-079, TSF-021, TSF79]; [acetominofene]

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04182984 (ClinicalTrials.gov)	November 4, 2019	26/11/2019	TheRapeutic Effect of Different immunosuppressAnts on Non-Thymoma Ocular Myasthenia Gravis: a Real-world Study	TheRapeutic Effect of Different immunosuppressAnts on Non-Thymoma Ocular Myasthenia Gravis: a Real-world Study	Ocular Myasthenia Gravis	Drug: Symptomatic Treatment, Steroids, Immunosuppressive Agents( azathioprine, tacrolimus, Mycophenolate Mofetil)	Tang-Du Hospital	NULL	Recruiting	18 Years	75 Years	All	200		China
2	JPRN-UMIN000015019	2014/09/02	02/09/2014	Initial therapy for myasthenia gravis of combined therapy for tacrolimus and IVIG		Myasthenia gravis	Tacrolimus and IVIG	Kansai medical university	NULL	Recruiting	Not applicable	Not applicable	Male and Female	20	Not applicable	Japan
3	JPRN-UMIN000007679	2012/04/01	09/04/2012	Randomized comparative study on efficacy and safety of tacrolimus, prednisolone or placebo in ocular myasthenia gravis patients		Myasthenia gravis	Administration of tacrolimus 3 mg/day Administration of prednisolone 5 mg/day anticholinesterases	Department of Neurology, Chiba University Graduate School of Medicine	NULL	Recruiting	20years-old	Not applicable	Male and Female	60	Not selected	Japan
4	JPRN-UMIN000007671	2012/04/01	09/04/2012	Randomized comparative study on efficacy and safety of reduced-dose steroid combined with tacrolimus vs conventional-dose steroid in late- or elderly-onset myasthenia gravis patients		Myasthenia gravis	Administration of prednisolone 35 mg/day with tacrolimus 3mg a day Administration of prednisolone 50 mg/day	Department of Neurology, Chiba University Graduate School of Medicine	NULL	Recruiting	50years-old	Not applicable	Male and Female	40	Not applicable	Japan
5	NCT01325571 (ClinicalTrials.gov)	March 2011	16/3/2011	A Study to Compare the Efficacy and Safety of Tacrolimus Capsules in Patient With Myasthenia Gravis	A Randomized, Double-blinded, Placebo-controlled, and Multi-centered Clinical Trial Evaluating the Efficacy and Safety of Tacrolimus Capsule in Myasthenia Gravis That Was Insufficiently Treated by Glucocorticoid Therapy	Myasthenia Gravis	Drug: Tacrolimus capsule;Drug: Placebo	Astellas Pharma Inc	Astellas Pharma China, Inc.	Completed	18 Years	70 Years	Both	83	Phase 3	China
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
6	NCT00309088 (ClinicalTrials.gov)	April 2006	29/3/2006	FK506 Phase 3 Study: a Study for Steroid Non-resistant Myasthenia Gravis (MG) Patients	FK506 Phase 3 Study: a Double Blind Placebo Controlled Study for Steroid Non-Resistant Myasthenia Gravis Patients	Myasthenia Gravis	Drug: tacrolimus;Drug: placebo	Astellas Pharma Inc	NULL	Completed	16 Years	64 Years	Both	80	Phase 3	Japan
7	NCT00309101 (ClinicalTrials.gov)	February 2006	29/3/2006	An Open Study for Steroid Resistant, Non-Thymectomized MG Patients	FK506 Phase 3 Study: An Open Study for Steroid Resistant, Non-Thymectomized MG Patients	Myasthenia Gravis	Drug: tacrolimus	Astellas Pharma Inc	NULL	Completed	16 Years	64 Years	Both	11	Phase 3	Japan

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT04182984
(ClinicalTrials.gov)

November 4, 2019

26/11/2019

TheRapeutic Effect of Different immunosuppressAnts on Non-Thymoma Ocular Myasthenia Gravis: a Real-world Study

Ocular Myasthenia Gravis

Drug: Symptomatic Treatment, Steroids, Immunosuppressive Agents( azathioprine, tacrolimus, Mycophenolate Mofetil)

Tang-Du Hospital

NULL

Recruiting

18 Years

75 Years

All

200

China

JPRN-UMIN000015019

2014/09/02

02/09/2014

Initial therapy for myasthenia gravis of combined therapy for tacrolimus and IVIG

Myasthenia gravis

Tacrolimus and IVIG

Kansai medical university

NULL

Recruiting

Not applicable

Male and Female

Not applicable

Japan

JPRN-UMIN000007679

2012/04/01

09/04/2012

Randomized comparative study on efficacy and safety of tacrolimus, prednisolone or placebo in ocular myasthenia gravis patients

Myasthenia gravis

Administration of tacrolimus 3 mg/day
Administration of prednisolone 5 mg/day
anticholinesterases

Department of Neurology, Chiba University Graduate School of Medicine

NULL

Recruiting

20years-old

Not applicable

Male and Female

Not selected

Japan

JPRN-UMIN000007671

2012/04/01

09/04/2012

Randomized comparative study on efficacy and safety of reduced-dose steroid combined with tacrolimus vs conventional-dose steroid in late- or elderly-onset myasthenia gravis patients

Myasthenia gravis

Administration of prednisolone 35 mg/day with tacrolimus 3mg a day
Administration of prednisolone 50 mg/day

Department of Neurology, Chiba University Graduate School of Medicine

NULL

Recruiting

50years-old

Not applicable

Male and Female

Not applicable

Japan

NCT01325571
(ClinicalTrials.gov)

March 2011

16/3/2011

A Study to Compare the Efficacy and Safety of Tacrolimus Capsules in Patient With Myasthenia Gravis

A Randomized, Double-blinded, Placebo-controlled, and Multi-centered Clinical Trial Evaluating the Efficacy and Safety of Tacrolimus Capsule in Myasthenia Gravis That Was Insufficiently Treated by Glucocorticoid Therapy

Myasthenia Gravis

Drug: Tacrolimus capsule;Drug: Placebo

Astellas Pharma Inc

Astellas Pharma China, Inc.

Completed

18 Years

70 Years

Both

Phase 3

China

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT00309088
(ClinicalTrials.gov)

April 2006

29/3/2006

FK506 Phase 3 Study: a Study for Steroid Non-resistant Myasthenia Gravis (MG) Patients

FK506 Phase 3 Study: a Double Blind Placebo Controlled Study for Steroid Non-Resistant Myasthenia Gravis Patients

Myasthenia Gravis

Drug: tacrolimus;Drug: placebo

Astellas Pharma Inc

NULL

Completed

16 Years

64 Years

Both

Phase 3

Japan

NCT00309101
(ClinicalTrials.gov)

February 2006

29/3/2006

An Open Study for Steroid Resistant, Non-Thymectomized MG Patients

FK506 Phase 3 Study: An Open Study for Steroid Resistant, Non-Thymectomized MG Patients

Myasthenia Gravis

Drug: tacrolimus

Astellas Pharma Inc

NULL

Completed

16 Years

64 Years

Both

Phase 3

Japan